This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Similar Posts
2023 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee
This page contains the meeting materials for the Cardiovascular & Renal Drugs Advisory Committee meetings for 2023.FDA Rationale for Recognition Decision: Isavuconazonium sulfate
FDA Rationale for Recognition Decision: Isavuconazonium sulfateUnipack LLC – 716621 – 12/19/2025
CGMP/Finished Pharmaceuticals/AdulteratedNovel Drug Approvals for 2022
Innovative drugs often mean new treatment options for patients and advances in health care for the American public.Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide /Aluminum Hydroxide /Simethicone Oral Suspension Due to Microbial Contamination
Lawrence, Kansas – Plastikon Healthcare, LLC is voluntarily recalling one (1) lot of Milk of Magnesia 2400 mg/10 mL Oral Suspension, one (1) lot of Milk of Magnesia 2400 mg/30 mL Oral Suspension, eleven (11) lots of Magnesium Hydroxide 1200 mg/Aluminum Hydroxide 1200 mg/Simethicone 120 mg per 30 mLSummary of Color Additives for Use in the United States in Foods, Drugs, Cosmetics, and Medical Devices
Summary of Color Additives for Use in the United States in Foods, Drugs, Cosmetics, and Medical Devices